SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF is surging as comments from Donald Trump about the Iran conflict being "very complete, pretty much" trigger a broad market rebound, though many in the community are highly skeptical, calling it a "Trump pump" or "manipulation" and questioning the true de-escalation given ongoing geopolitical tensions. The rapid turnaround has sparked intense debate over the market's current volatility and underlying catalysts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid escalating Middle East tensions, with initial surges driven by Strait of Hormuz disruption fears and production cuts now battling signals of de-escalation from presidential remarks and G7 discussions on strategic oil reserve releases. This has led to a polarized community debate on its immediate trajectory.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting robust Q4 earnings that significantly surpassed expectations, driven by strong sales of its rare disease drug MIPLYFFA and marking the company's achievement of profitability. This financial performance is fueling widespread community excitement, with many speculating on a potential short squeeze and re-evaluating the stock's value as a commercially successful rare disease player.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as it begins early U.S. operations under a White House-backed eVTOL Integration Pilot Program and launches Uber Air in Dubai, marking significant progress toward commercial air taxi services. The community is actively discussing these milestones alongside recent positive earnings and ongoing comparisons with competitor Archer Aviation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is drawing significant attention following its recent U.S. Department of Energy agreement for Project TEFLA, a crucial step in integral molten salt reactor fuel production, which the community sees as a catalyst for its long-term potential in powering AI data centers and positions it as an undervalued player in the advanced nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is surging, fueling a significant short squeeze, after reports of President Trump's optimistic statements suggested the Iran war is 'very complete, pretty much,' leading to a market rebound and a sharp drop in oil prices amid divided investor sentiment.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending following its Q3 earnings, which saw a significant EPS beat alongside a revenue miss, sparking debate among investors. Bulls emphasize the robust performance of its high-margin inside sales, particularly pizza, and positive fiscal year guidance, while bears point to slowing growth in prepared food and flat fuel volumes, questioning its valuation.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals is surging due to overwhelmingly positive Phase 3 results for its lead epilepsy treatment, azetukalner, which demonstrated robust seizure reduction and outperformed previous studies, positioning it as a differentiated KV7 potassium channel opener. While a subsequent common shares offering has sparked some debate, the market is actively discussing the drug's strong efficacy and potential for an upcoming NDA filing.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which supports advancing to Phase 3, alongside an oversubscribed $160 million private placement financing. The community is vigorously discussing the biotech's significant price and volume surge, anticipating continued momentum for its promising clinical pipeline.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is trending as its recent earnings showcased strong demand for AI systems and significant growth in its networking segment, boosted by the completed Juniper Networks acquisition. The community is actively discussing the company's strategic shift to an AI-driven hybrid cloud and networking powerhouse, anticipating substantial market share gains despite lingering concerns about short-term outlooks and rising component costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Atara said that its partner Pierre Fabre Pharmaceuticals submitted a briefing to the FDA addressing its concerns.&nbsp;</li><li>Atara had transferred its application seeking approval for tabelecleucel to a U.S. pharma unit of Pierre Fabre Laboratories in November.</li></ul>Shares of Atara Biotherapeutics, Inc. (ATRA) rose 7% on Tuesday after the company said that its partner has sought a meeting with the U.S. Food and Drug Administration to address the concerns raised by the agency while it refused approval for its immunotherapy tabelecleucel in January. &nbsp;FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (PTLD) earlier this year. &nbsp;The FDA said in a letter to the company that it is unable to approve the application in present form, stating that the trial conducted by the company is not adequate to provide evidence of effectiveness for accelerated approval. The authority also stated that the trial’s interpretability is confounded due to trial study design, conduct, and analysis.<h2 class="st-heading-2">Atara Pushes Back</h2>On Tuesday, Atara <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260303134105/en/Atara-Biotherapeutics-Provides-Regulatory-Update-on-Tabelecleucel">said</a> that its partner Pierre Fabre Pharmaceuticals submitted a briefing to the FDA addressing its concerns and provided additional context and clarification that the study was indeed adequate, well-controlled, and sufficient to support the tabelecleucel application.The firm also provided summaries of updated, longer-term efficacy data from the study, additional supportive data from the tab-cel development program and post-marketing data in Europe that will be included in a potential resubmission, it said.“With our partners at Pierre Fabre Pharmaceuticals, we are eager to engage in a constructive discussion with the FDA to reach a path forward for tabelecleucel,” said Atara CEO Cokey Nguyen while also noting the “ultra-rare nature” of PTLD.Epstein-Barr Virus (EBV)-positive Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious, often life-threatening complication after organ or stem cell transplantation, characterized by uncontrolled growth of EBV-infected B-cells due to suppressed immunity, ranging from mononucleosis-like illness to aggressive lymphoma.Atara had transferred its application seeking approval for tabelecleucel to a U.S. pharma unit of Pierre Fabre Laboratories in November.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATRA rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/ATRA">ATRA stock</a> has fallen 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-jeff-schmid-says-apex-bank-does-not-have-room-to-be-complacent-about-inflation-report/cZdekrARIP0">Fed’s Jeff Schmid Says Apex Bank Does Not Have Room To Be ‘Complacent’ About Inflation: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection

FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease earlier this year.

Equity

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics Provides a Business Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea sold 80,554 shares of Atara Biotherapeutics stock in a transaction dated Monday, January 12th. The...

<ul class="summary-bullets"><li>This is the second time that the FDA has refused to approve EBVALLO.</li><li>Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design.</li><li>Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November.</li></ul>Shares of Atara Biotherapeutics, Inc. (ATRA) slumped 53% on Monday after the U.S. Food and Drug Administration refused approval for its immunotherapy EBVALLO in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease.Epstein-Barr Virus (EBV)-positive Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious, often life-threatening complication after organ or stem cell transplantation, characterized by uncontrolled growth of EBV-infected B-cells due to suppressed immunity, ranging from mononucleosis-like illness to aggressive lymphoma.The FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business">said</a> in a letter to the company that it is unable to approve its EBVALLO application in present form, stating that the trial conducted by the company is not adequate to provide evidence of effectiveness for accelerated approval. The authority also stated that the trial’s interpretability is confounded due to trial study design, conduct, and analysis.<h2 class="st-heading-2">Back-To-Back Rejection</h2>This is the second time that the FDA has refused to approve EBVALLO. The company resubmitted its application in 2025 after it was rejected the first time due to a concern with manufacturing.Atara said in a statement on Monday that the FDA’s new position is “contrary” to its prior alignment with the company on the trial design. “This prior alignment had been reached by Atara and the FDA through multiple, documented meetings held over the past five plus years,” it said. &nbsp;Atara had transferred its application seeking approval for EBVALLO to a U.S. pharma unit of Pierre Fabre Laboratories in November. Pierre will now seek a meeting with the FDA, which is expected to be granted within 45 days. The company said that it intends to urgently interact with FDA to find a path forward for EBVALLO approval with Pierre.<h2 class="st-heading-2">Company’s Reaction</h2>Atara CEO Cokey Nguyen said that the company is “surprised and disappointed” by the FDA decision.“The issues highlighted in the CRL were issues Atara and the FDA aligned on in previous reviews or communications. We had aligned with the agency to accept an Accelerated Approval and to perform a post marketing confirmatory study to support full approval. We proceeded with the BLA submission on this basis and continued all remediation efforts after the resubmission in 2025, in full reliance of the confirmation provided by the FDA,” the CEO said.Atara ended 2025 with cash, cash equivalents and short-term investments of $8.5 million after trimming down workforce by about 90% year-over-year and transitioning almost all activities and costs pertaining to EBVALLO to Pierre Fabre laboratories.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATRA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed disappointment over the news.<stembedurl>https://www.stocktwits.com/BwesY/message/641538764</stembedurl>Yet another said that they added more shares of the company. “I am already sensing a big fight back,” they said.<stembedurl>https://www.stocktwits.com/Niddi/message/641533765</stembedurl><a href="https://stocktwits.com/symbol/ATRA">ATRA stock</a> has dropped 60% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’

The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.

FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks

Atara Biotherapeutics stock drops on FDA rejection of EBVALLO BLA for serious post-transplant complication. FDA raises new concerns.read more...

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION PIERRE FABRE...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRA News

ATRAAtara Biotherapeutics Inc